Results 141 to 150 of about 910,008 (206)

NTRK gene fusion testing and management in lung cancer

Cancer Treatment Reviews
Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are recurrent oncogenic drivers found in a variety of solid tumours, including lung cancer. Several tropomyosin receptor kinase (TRK) inhibitors have been developed to treat tumours with NTRK gene fusions.
Repetto, M, Chiara Garassino, M, Loong, HH, Lopez-Rios, F, Mok, T, Peters, S, Planchard, D, Popat, S, Rudzinski, ER, Drilon, A, Zhou, C   +10 more
openaire   +4 more sources

Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities [PDF]

, 2014
Breast cancer encompasses a collection of different diseases characterized by different biological and pathological features, clinical presentation, response to treatments, clinical behavior, and outcome.
Conte, Pierfranco, Dieci, Maria Vittoria, Dominici, Massimo, Guarneri, Valentina, Orvieto, Enrico   +4 more
core   +1 more source

Real-World Experience ofNTRKFusion–Positive Thyroid Cancer [PDF]

JCO Precision Oncology, 2022
Jong Chul Park, Arya Ashok, Chienying Liu, Hyunseok Kang   +3 more
openaire   +2 more sources

Adenocarcinoma of the esophagus and gastroesophageal junction: The evolving treatment landscape for locally advanced and metastatic disease in the era of immune checkpoint inhibitors and biomarker‐driven therapeutics

CA: A Cancer Journal for Clinicians, Volume 76, Issue 1, January/February 2026.
Laura V. M. Baum, Kimberly L. Johung, Joanna Gibson, Gabriel Cartagena, Daniel J. Boffa, Jill Lacy   +5 more
wiley   +1 more source

NTRK-rearranged spindle cell tumor with SPECC1L-NTRK3 fusion in the thoracic spine: a case report

Journal of Cancer Research and Clinical Oncology
Neurotrophic Tyrosine Receptor Kinase (NTRK)-rearranged spindle cell tumors are a category of soft tissue tumors characterized by rearrangements of the NTRK gene family (NTRK1, NTRK2, and NTRK3), which leads to distinct molecular genetics, morphological,
Mi Zhou, Huaiyuan Xu, Jianxiong Niu, Qibing Yang, Anqi Wang, Hao Wu, Xiangqin Wang, Meng Yang, Jinxin Hu, Qinglian Tang, Jin Wang   +10 more
doaj   +1 more source

From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis

Frontiers in Pharmacology
Introduction: The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions has facilitated the development of precision oncology. Two first-generation NTRK inhibitors (larotrectinib and entrectinib) are currently approved for the treatment ...
Zhiwei Cui, Zhen Zhai, De Xie, Lihui Wang, Feiyan Cheng, Siyu Lou, Fan Zou, Rumeng Pan, Shixue Chang, Haoyan Yao, Jing She, Yidan Zhang, Xinyuan Yang   +12 more
doaj   +1 more source

Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland

Acta Oncologica
Background: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers. Using the Auria Biobank in Finland, we aimed to identify and characterize patients with these gene fusions, and describe their clinical and tumor ...
Wei Zhang, Arndt A. Schmitz, Roosa E. Kallionpää, Merja Perälä, Niina Pitkänen, Mikko Tukiainen, Erika Alanne, Korinna Jöhrens, Renate Schulze-Rath, Bahman Farahmand, Jihong Zong   +10 more
doaj   +1 more source

Recent ATLAS results and preparations for Run 2

, 2015
The CERN LHC delivered 25/fb of proton-proton collision data in 2011-2012 at sqrt{s} = 7 - 8 TeV centre-of-mass energy to the ATLAS detector. These Run 1 data were used to discover the Higgs boson and measure its properties as well as to perform numerous
Pásztor, Gabriella
core  

High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategy

ESMO Gastrointestinal Oncology
Background: Currently, mismatch repair deficient/microsatellite instable (dMMR/MSI) status constitutes a validated predictive marker of response to immune checkpoint inhibitors (ICIs) in patients with metastatic colorectal cancer (mCRC).
M. Svrcek, A. Cayre, T. Samaille, R. Colle, L. Mas, P. Bourgoin, E. Guillerm, R. Cohen, F. Penault-Llorca, T. André, N. Radosevic-Robin   +10 more
doaj   +1 more source

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.

The Lancet Oncology, 2019
R. Doebele, A. Drilon, L. Paz-Ares, S. Siena, A. Shaw, A. Farago, C. Blakely, T. Seto, B. Cho, D. Tosi, B. Besse, S. Chawla, L. Bazhenova, J. Krauss, Y. Chae, M. Barve, I. Garrido-Laguna, Stephen V. Liu, P. Conkling, T. John, M. Fakih, D. Sigal, H. Loong, G. Buchschacher, P. Garrido, J. Nieva, C. Steuer, T. Overbeck, D. Bowles, E. Fox, T. Riehl, E. Chow-Maneval, B. Simmons, N. Cui, Ann Johnson, Susan Eng, T. Wilson, G. Demetri   +37 more
semanticscholar   +1 more source